Human ATP2B4/ATP2B2/MXRA1 ORF/cDNA clone-Lentivirus plasmid (NM_001684)

Cat. No.: pGMLP001604
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human ATP2B4/ATP2B2/MXRA1 Lentiviral expression plasmid for ATP2B4 lentivirus packaging, ATP2B4 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

Our GM-Lentiviral vector is seamlessly integrated with the GM lentivirus packaging system. Discover more about the GM lentivirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to ATP2B4/ATP2B2 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Total Price: $1747.2
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMLP001604
Gene Name ATP2B4
Accession Number NM_001684
Gene ID 493
Species Human
Product Type Lentivirus plasmid (overexpression)
Insert Length 3618 bp
Gene Alias ATP2B2,MXRA1,PMCA4,PMCA4b,PMCA4x
Fluorescent Reporter ZsGreen
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGACGAACCCATCAGACCGTGTCTTGCCTGCCAACTCGATGGCCGAGAGCCGTGAAGGGGACTTTGGCTGCACAGTAATGGAACTGAGGAAGCTCATGGAGCTGCGTTCAAGGGATGCACTGACCCAGATTAATGTCCACTATGGAGGTGTACAGAATCTCTGCAGTAGACTGAAAACCTCCCCTGTGGAAGGTCTGTCTGGGAACCCTGCAGATCTGGAGAAACGTAGGCAGGTGTTTGGACACAACGTGATCCCCCCCAAAAAGCCCAAGACTTTCTTAGAATTAGTGTGGGAAGCTCTTCAAGATGTCACGCTTATCATCCTGGAGATTGCAGCCATCATCTCCCTGGTCCTGTCCTTTTATCGCCCTGCTGGTGAAGAAAATGAACTGTGTGGTCAAGTCGCAACTACCCCAGAAGATGAAAATGAGGCACAAGCTGGCTGGATTGAGGGGGCAGCCATCCTTTTCTCAGTGATCATCGTGGTGTTAGTGACTGCCTTTAATGATTGGAGCAAAGAGAAGCAATTCCGGGGGCTGCAGTGCCGCATTGAACAGGAGCAAAAGTTCTCCATCATCCGAAACGGTCAACTCATCCAGCTCCCTGTGGCTGAGATTGTGGTTGGTGATATTGCCCAAGTCAAATACGGTGATCTGCTGCCTGCAGATGGAATCCTGATCCAAGGGAATGATCTGAAGATTGATGAGAGCTCTCTGACAGGGGAATCTGACCATGTCAAGAAGTCCCTGGACAAAGACCCCATGTTGCTCTCAGGGACCCATGTCATGGAAGGTTCTGGCCGGATGGTGGTGACAGCTGTTGGTGTCAACTCTCAGACTGGAATCATCCTTACTCTCTTGGGGGTCAATGAGGATGACGAAGGGGAGAAAAAGAAGAAAGGTAAAAAACAAGGAGTCCCTGAAAATCGCAACAAAGCAAAGACCCAAGACGGAGTGGCCCTGGAAATCCAGCCACTCAACAGCCAGGAGGGAATCGACAATGAGGAAAAGGACAAGAAGGCAGTCAAGGTGCCTAAAAAGGAGAAGTCAGTGCTGCAGGGCAAGCTGACTCGCCTGGCTGTTCAGATTGGGAAAGCCGGTCTGCTCATGTCTGCTCTCACGGTTTTCATCCTGATTCTATACTTTGTGATTGACAACTTTGTGATAAATCGCAGACCATGGCTCCCTGAGTGTACTCCCATCTACATCCAGTACTTTGTCAAGTTCTTCATCATCGGCATCACTGTACTGGTGGTGGCTGTGCCAGAGGGGCTGCCTCTGGCTGTCACCATCTCACTGGCCTACTCTGTGAAGAAAATGATGAAAGACAATAACCTAGTACGGCACTTGGATGCTTGTGAGACCATGGGCAACGCCACCGCCATCTGCTCTGATAAGACAGGCACGTTGACCATGAACCGCATGACTGTGGTACAAGCTTATATTGGGGGCATCCATTACCGTCAAATCCCAAGCCCTGATGTCTTCCTGCCCAAAGTCCTGGACCTCATTGTCAATGGCATTTCTATCAACAGTGCTTATACCTCCAAGATTCTGCCTCCAGAGAAGGAGGGAGGCCTGCCTCGGCAGGTGGGCAACAAGACCGAGTGTGCTCTGCTAGGCTTTGTCACAGATCTGAAGCAGGATTATCAGGCTGTGCGTAATGAAGTGCCCGAGGAGAAGCTCTACAAGGTGTACACCTTTAACTCAGTGCGCAAGTCAATGAGCACCGTCATCAGGAATCCCAACGGTGGCTTCCGTATGTACAGCAAGGGCGCCTCTGAGATCATCTTGCGCAAGTGTAATCGAATCCTGGACCGGAAAGGGGAAGCAGTGCCATTCAAGAATAAAGACAGAGATGATATGGTACGCACTGTCATCGAGCCCATGGCCTGTGATGGACTCCGGACTATCTGCATAGCTTACCGGGACTTCGATGACACAGAGCCCTCTTGGGACAATGAGAATGAGATCCTCACCGAACTGACCTGTATCGCGGTGGTGGGCATTGAGGACCCTGTGCGCCCAGAGGTGCCAGATGCTATTGCCAAATGCAAACAAGCTGGCATTACTGTCAGAATGGTGACAGGTGACAACATCAACACAGCCCGGGCCATTGCCACCAAATGTGGCATTCTGACACCTGGGGATGACTTCCTGTGCTTAGAAGGCAAAGAATTCAACCGGCTCATCCGCAACGAGAAAGGCGAGGTAGAGCAAGAAAAGCTGGACAAGATCTGGCCTAAGCTTCGGGTCCTGGCGCGATCTTCTCCCACTGACAAGCACACCCTGGTGAAAGGCATAATTGACAGCACTGTTGGGGAACACCGGCAGGTCGTGGCTGTCACTGGTGATGGCACAAATGACGGGCCTGCTCTGAAGAAAGCGGATGTTGGTTTTGCCATGGGCATCGCAGGCACAGATGTAGCAAAGGAGGCTTCAGACATCATCCTAACAGATGACAACTTCACCAGCATTGTGAAGGCAGTGATGTGGGGACGAAATGTCTATGACAGCATCTCCAAGTTCCTGCAGTTCCAGCTCACTGTCAATGTGGTGGCCGTGATTGTAGCCTTCACTGGAGCCTGTATCACTCAGGATTCCCCATTGAAAGCTGTGCAGATGTTGTGGGTTAATCTGATCATGGACACTTTTGCTTCATTGGCCCTGGCCACAGAGCCCCCTACGGAATCTCTGTTGAAGCGGCGCCCCTATGGCCGAAATAAGCCTCTGATCTCACGCACTATGATGAAGAACATCTTGGGCCATGCATTCTATCAGCTCATTGTCATCTTTATCCTTGTCTTTGCGGGTGAGAAATTCTTTGATATTGATAGTGGGAGGAAGGCACCTCTACATTCACCACCCAGCCAGCACTATACCATTGTTTTTAACACCTTCGTGCTGATGCAGCTCTTCAATGAAATCAACTCCCGAAAGATCCATGGAGAGAAGAACGTCTTTTCAGGCATCTACCGCAACATTATCTTCTGCTCTGTAGTCTTGGGCACATTCATCTGCCAGATTTTCATCGTGGAATTTGGGGGTAAACCCTTCAGTTGTACAAGCCTCAGCCTGTCTCAGTGGCTGTGGTGTCTCTTCATTGGGATTGGAGAACTTCTGTGGGGCCAGTTCATCTCCGCAATACCTACCCGATCCCTGAAGTTCCTGAAGGAGGCTGGGCATGGCACCACCAAAGAGGAGATCACCAAGGATGCCGAGGGACTGGATGAGATTGACCATGCTGAGATGGAGCTGCGCCGAGGCCAGATCCTCTGGTTCCGGGGCCTGAACCGTATCCAGACTCAGATCAAAGTGGTCAAAGCGTTCCATAGTTCCCTCCACGAAAGCATTCAGAAACCCTACAACCAAAAGTCCATCCACAGCTTCATGACCCACCCTGAATTCGCCATAGAGGAGGAGTTGCCACGAACACCACTCCTGGATGAGGAAGAGGAGGAAAATCCTGACAAGGCTTCTAAGTTTGGGACTAGGGTGCTCCTGTTGGATGGTGAGGTCACTCCATATGCCAATACAAACAACAATGCGGTGGATTGCAACCAAGTGCAGCTCCCCCAGTCGGACAGCTCTCTACAGAGCCTAGAGACATCAGTTTGA
ORF Protein Sequence MTNPSDRVLPANSMAESREGDFGCTVMELRKLMELRSRDALTQINVHYGGVQNLCSRLKTSPVEGLSGNPADLEKRRQVFGHNVIPPKKPKTFLELVWEALQDVTLIILEIAAIISLVLSFYRPAGEENELCGQVATTPEDENEAQAGWIEGAAILFSVIIVVLVTAFNDWSKEKQFRGLQCRIEQEQKFSIIRNGQLIQLPVAEIVVGDIAQVKYGDLLPADGILIQGNDLKIDESSLTGESDHVKKSLDKDPMLLSGTHVMEGSGRMVVTAVGVNSQTGIILTLLGVNEDDEGEKKKKGKKQGVPENRNKAKTQDGVALEIQPLNSQEGIDNEEKDKKAVKVPKKEKSVLQGKLTRLAVQIGKAGLLMSALTVFILILYFVIDNFVINRRPWLPECTPIYIQYFVKFFIIGITVLVVAVPEGLPLAVTISLAYSVKKMMKDNNLVRHLDACETMGNATAICSDKTGTLTMNRMTVVQAYIGGIHYRQIPSPDVFLPKVLDLIVNGISINSAYTSKILPPEKEGGLPRQVGNKTECALLGFVTDLKQDYQAVRNEVPEEKLYKVYTFNSVRKSMSTVIRNPNGGFRMYSKGASEIILRKCNRILDRKGEAVPFKNKDRDDMVRTVIEPMACDGLRTICIAYRDFDDTEPSWDNENEILTELTCIAVVGIEDPVRPEVPDAIAKCKQAGITVRMVTGDNINTARAIATKCGILTPGDDFLCLEGKEFNRLIRNEKGEVEQEKLDKIWPKLRVLARSSPTDKHTLVKGIIDSTVGEHRQVVAVTGDGTNDGPALKKADVGFAMGIAGTDVAKEASDIILTDDNFTSIVKAVMWGRNVYDSISKFLQFQLTVNVVAVIVAFTGACITQDSPLKAVQMLWVNLIMDTFASLALATEPPTESLLKRRPYGRNKPLISRTMMKNILGHAFYQLIVIFILVFAGEKFFDIDSGRKAPLHSPPSQHYTIVFNTFVLMQLFNEINSRKIHGEKNVFSGIYRNIIFCSVVLGTFICQIFIVEFGGKPFSCTSLSLSQWLWCLFIGIGELLWGQFISAIPTRSLKFLKEAGHGTTKEEITKDAEGLDEIDHAEMELRRGQILWFRGLNRIQTQIKVVKAFHSSLHESIQKPYNQKSIHSFMTHPEFAIEEELPRTPLLDEEEEENPDKASKFGTRVLLLDGEVTPYANTNNNAVDCNQVQLPQSDSSLQSLETSV

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-MP0106-Ab Anti-AT2B4/ ATP2B4/ ATP2B2 monoclonal antibody
    Target Antigen GM-Tg-g-MP0106-Ag ATP2B4 VLP (virus-like particle)
    ORF Viral Vector pGMLP001604 Human ATP2B4 Lentivirus plasmid
    ORF Viral Vector vGMLP001604 Human ATP2B4 Lentivirus particle


    Target information

    Target ID GM-MP0106
    Target Name ATP2B4
    Gene Group Identifier
    （Target Gene ID in Homo species)         		493
    Gene ID 100049920 (Equus caballus), 101101538 (Felis catus), 282146 (Bos taurus), 29600 (Rattus norvegicus)
    381290 (Mus musculus), 403731 (Canis lupus familiaris), 493 (Homo sapiens), 574317 (Macaca mulatta)
    Gene Symbols & Synonyms ATP2B4,Atp2b4,PMCA4,Pmca4,MXRA1,ATP2B2,PMCA4b,PMCA4x,ATP2B1
    Target Alternative Names ATP2B1,ATP2B2,ATP2B4,Atp2b4,MXRA1,Matrix-remodeling-associated protein 1,PMCA4,PMCA4b,PMCA4x,Plasma membrane calcium ATPase isoform 4,Plasma membrane calcium pump isoform 4,Plasma membrane calcium-transporting ATPase 4,Pmca4
    Uniprot Accession D3K0R6,P23634,Q64542,Q6Q477
    Additional SwissProt Accessions: D3K0R6,Q64542,Q6Q477,P23634
    Uniprot Entry Name
    Protein Sub-location Transmembrane Protein
    Category
    Disease
    Disease from KEGG Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Salivary secretion, Pancreatic secretion, Mineral absorption
    Gene Ensembl ENSECAG00000002919, ENSBTAG00000014059, ENSMUSG00000026463, ENSCAFG00845019471, ENSG00000058668, ENSMMUG00000021116
    Target Classification


    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.